The round was led by Unilever Technology Ventures, Novartis Venture Funds, the ATDC Seed Capital Fund, as well as a number of private investors.
Rafael Andino, founder of Biofisica, said: “We are very pleased that our investors continue to show a tremendous vote of confidence for the progress that we’re making with our business plan and the recognition that POSiFECT serves a critical need in the wound care market.”